← 產業報告目錄

Vitiligo Treatment Market Research Report Information by Type (Segmental Vitiligo, Non-Segmental Vitiligo), By Treatment (Therapy, Surgery, Medication), By End-User (Hospitals, Ambulatory Clinics, Others), and Region (North America, Europe, Asia-Pacific, and Rest of the World)—Forecast till 2030

出版商 Market Research Future產業別 Healthcare & Life Sciences出版日期 2024-08-10頁數 123報告編號 MRFRHC6970CR

授權報價

Single User Price$4,950 USD
Multi User Licence (up to 10 users)$5,950 USD
Enterprisewide Price (Global Site License)$7,250 USD
洽詢購買 申請 Sample

報告摘要

Vitiligo Treatment Market Research Report Information by Type (Segmental Vitiligo, Non-Segmental Vitiligo), By Treatment (Therapy, Surgery, Medication), By End-User (Hospitals, Ambulatory Clinics, Others), and Region (North America, Europe, Asia-Pacific, and Rest of the World)—Forecast till 2030 Market Overview The Vitiligo Treatment Market industry is expected to grow at a compound annual growth rate (CAGR) of 6.20% over the forecast period. The growing relevance of aesthetic appeal and awareness, the rising prevalence of vitligo, and innovations in treatment options are propelling the industry forward. Consumers' beauty consciousness has increased significantly in recent years because of expanding awareness of various aesthetic treatments, rising per capita income, and the adoption of internet platforms. According to the International Society of Aesthetic Plastic Surgery (ISAPS), worldwide total non-surgical procedures increased by 27.3% between 2015 and 2019. Furthermore, the American Society of Plastic Surgeons (ASPS) reports that the number of minimally invasive cosmetic operations increased by around 200% between 2000 and 2017. Furthermore, around 15.9 million minimally invasive cosmetic operations were performed in 2018, up 2% from 2017. Market Segment insights The Vitiligo Treatment Market is divided into two types: segmental vitiligo and non-segmental vitiligo. The market is segmented based on treatment options such as therapy, surgery, and medication. The market is segmented by end user, which includes hospitals, ambulatory clinics, and others. Regional insights The North American Vitiligo Treatment Market held the biggest market share in 2023. Due to improved healthcare infrastructure and increased awareness of skin problems. The region's significant concentration on research and development has resulted in the launch of novel treatments such as enhanced phototherapy, biologics, and topical medicines. The European Vitiligo Treatment Market is predicted to account for the second-largest market share due to favorable health legislation and a tendency toward integrating Vitiligo Treatment. Furthermore, the German Vitiligo Treatment Market was found to have the greatest market share, while the France Vitiligo Treatment Market is predicted to be the fastest-growing market in the European area. The Asia-Pacific Vitiligo Treatment market is predicted to develop at the quickest rate between 2024 and 2030. This is due to improved healthcare infrastructure, combined with increased healthcare expenditures, which allow for better access to innovative therapies. Furthermore, the increasing frequency of vitiligo and the growing need for cosmetic and dermatological therapies are key motivators. Major Players Incyte (US), Bausch Health Companies Inc. (Canada), Koninklijke Philips N.V. (Netherlands), Reddy's Laboratories Ltd. (India), Strata Skin Sciences (US), Clinuvel Pharmaceuticals Ltd. (Australia), ISSAR Pharmaceuticals Pvt. Ltd. (India), Kernel Medical Equipment CO., LTD. (China), LightSources (US), and Roivant Sciences Ltd. (Switzerland) are among the key companies in the Vitiligo Treatment Market.
目錄 Table of Contents
TABLE OF CONTENTS 1 EXECUTIVE SUMMARY 1.1 OVERVIEW 1.1.1 MARKET SYNOPSIS 2 MARKET INTRODUCTION 2.1 DEFINITION 2.2 SCOPE OF THE STUDY 2.3 RESEARCH OBJECTIVE 2.4 LIST OF ASSUMPTIONS 3 RESEARCH METHODOLOGY 3.1 OVERVIEW 3.2 DATA MINING 3.3 SECONDARY RESEARCH 3.4 PRIMARY RESEARCH 3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS 3.5 FORECASTING TECHNIQUES 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 3.6.1 BOTTOM-UP APPROACH 3.6.2 TOP-DOWN APPROACH 3.7 DATA TRIANGULATION 3.8 VALIDATION 4 MARKET DYNAMICS 4.1 OVERVIEW 4.2 DRIVERS 4.2.1 GROWING IMPORTANCE OF THE AESTHETIC APPEAL AND AWARENESS 4.2.2 INCREASING PREVALENCE OF VITLIGO 4.3 RESTRAINTS 4.3.1 LACK OF TRAINED PROFESSIONALS 4.4 OPPORTUNITIES 4.4.1 RISING NUMBER OF CLINICAL TRIALS 5 MARKET FACTOR ANALYSIS 5.1 VALUE CHAIN ANALYSIS 5.1.1 R&D 5.1.2 MANUFACTURING 5.1.3 DISTRIBUTION & SALES 5.1.4 POST-SALES MONITORING 5.2 PORTER'S FIVE FORCES MODEL 5.2.1 THREAT OF NEW ENTRANTS 5.2.2 BARGAINING POWER OF SUPPLIERS 5.2.3 THREAT OF SUBSTITUTES 5.2.4 BARGAINING POWER OF BUYERS 5.2.5 INTENSITY OF RIVALRY 5.3 IMPACT OF COVID-19 ON THE VITILIGO TREATMENT MARKET 5.3.1 IMPACT ON SUPPLY CHAIN 5.3.2 IMPACT ON REGION 5.3.3 IMPACT ON DEMAND AND SUPPLY 6 GLOBAL VITILIGO TREATMENT MARKET, BY TYPE 6.1 OVERVIEW 6.2 SEGMENTAL VITILIGO 6.3 NON-SEGMENTAL VITILIGO 7 GLOBAL VITILIGO TREATMENT MARKET, BY TREATMENT TYPE 7.1 OVERVIEW 7.2 THERAPY 7.2.1 DEPIGMENTATION 7.2.2 LIGHT 7.3 SURGERY 7.3.1 SKIN GRAFTING 7.3.2 BLISTER GRAFTING 7.3.3 MICRO-PIGMENTATION 7.4 MEDICATION 7.4.1 TOPICAL CORTICOSTEROIDS 7.4.2 IMMUNOSUPPRESSIVE 8 GLOBAL VITILIGO TREATMENT MARKET, BY END USER 8.1 OVERVIEW 8.2 HOSPITALS 8.3 AMBULATORY CLINICS 8.4 OTHERS 9 GLOBAL VITILIGO TREATMENT MARKET, BY REGION 9.1 OVERVIEW 9.2 NORTH AMERICA 9.2.1 US 9.2.2 CANADA 9.3 EUROPE 9.3.1 GERMANY 9.3.2 FRANCE 9.3.3 UK 9.3.4 ITALY 9.3.5 SPAIN 9.3.6 REST OF EUROPE 9.4 ASIA-PACIFIC 9.4.1 CHINA 9.4.2 JAPAN 9.4.3 INDIA 9.4.4 SOUTH KOREA 9.4.5 AUSTRALIA 9.4.6 REST OF ASIA-PACIFIC 9.5 REST OF THE WORLD 9.5.1 MIDDLE EAST 9.5.2 AFRICA 9.5.3 LATIN AMERICA 10 COMPETITIVE LANDSCAPE 10.1 OVERVIEW 10.2 COMPETITIVE BENCHMARKING 10.3 MAJOR GROWTH STRATEGY IN VITILIGO TREATMENT MARKET 10.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN VITILIGO TREATMENT MARKET 10.5 KEY DEVELOPMENT ANALYSIS 10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 10.6.1 PRODUCT APPROVALS/PRODUCT LAUNCHES/DRUG PIPELINE 10.6.2 MERGERS & ACQUISITIONS 10.7 MAJOR PLAYERS SALES ANALYSIS 10.7.1 SALES & OPERATING INCOME, 2022 10.7.2 MAJOR PLAYERS R&D ANALYSIS, 2022 11 COMPANY PROFILE 11.1 INCYTE 11.1.1 COMPANY OVERVIEW 11.1.2 FINANCIAL OVERVIEW 11.1.3 PRODUCTS OFFERED 11.1.4 KEY DEVELOPMENTS 11.1.5 SWOT ANALYSIS 11.1.6 KEY STRATEGIES 11.2 BAUSCH HEALTH COMPANIES INC. 11.2.1 COMPANY OVERVIEW 11.2.2 FINANCIAL OVERVIEW 11.2.3 PRODUCTS OFFERED 11.2.4 KEY DEVELOPMENTS 11.2.5 SWOT ANALYSIS 11.2.6 KEY STRATEGIES 11.3 KONINKLIJKE PHILIPS N.V. 11.3.1 COMPANY OVERVIEW 11.3.2 FINANCIAL OVERVIEW 11.3.3 PRODUCTS OFFERED 11.3.4 KEY DEVELOPMENTS 11.3.5 SWOT ANALYSIS 11.3.6 KEY STRATEGIES 11.4 DR. REDDY'S LABORATORIES LTD. 11.4.1 COMPANY OVERVIEW 11.4.2 FINANCIAL OVERVIEW 11.4.3 PRODUCTS OFFERED 11.4.4 KEY DEVELOPMENTS 11.4.5 SWOT ANALYSIS 11.4.6 KEY STRATEGIES 11.5 STRATA SKIN SCIENCES 11.5.1 COMPANY OVERVIEW 11.5.2 FINANCIAL OVERVIEW 11.5.3 PRODUCTS OFFERED 11.5.4 KEY DEVELOPMENTS 11.5.5 KEY STRATEGIES 11.6 CLINUVEL PHARMACEUTICALS LTD 11.6.1 COMPANY OVERVIEW 11.6.2 FINANCIAL OVERVIEW 11.6.3 PRODUCTS OFFERED 11.6.4 KEY DEVELOPMENTS 11.6.5 SWOT ANALYSIS 11.6.6 KEY STRATEGIES 11.7 ISSAR PHARMACEUTICALS PVT. LTD. 11.7.1 COMPANY OVERVIEW 11.7.2 FINANCIAL ANALYSIS 11.7.3 PRODUCTS OFFERED 11.7.4 KEY DEVELOPMENTS 11.7.5 KEY STRATEGIES 11.8 KERNEL MEDICAL EQUIPMENT CO., LTD. 11.8.1 COMPANY OVERVIEWS 11.8.2 FINANCIAL OVERVIEW 11.8.3 PRODUCTS OFFERED 11.8.4 KEY DEVELOPMENTS 11.8.5 KEY STRATEGIES 11.9 LIGHTSOURCES 11.9.1 COMPANY OVERVIEW 11.9.2 FINANCIAL ANALYSIS 11.9.3 PRODUCTS OFFERED 11.9.4 KEY DEVELOPMENTS 11.9.5 KEY STRATEGIES 11.10 ROIVANT SCIENCES LTD. 11.10.1 COMPANY OVERVIEW 11.10.2 FINANCIAL ANALYSIS 11.10.3 PRODUCTS OFFERED 11.10.4 KEY DEVELOPMENTS 11.10.5 PRODUCTS OFFERED 11.10.6 KEY STRATEGIES 12 APPENDIX 12.1 REFERENCES 12.2 RELATED REPORTS
圖表清單 List of Tables & Figures
LIST OF TABLES TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS TABLE 2 GLOBAL VITILIGO TREATMENT MARKET, BY TYPE, 2019–2030 (USD BILLION) TABLE 3 GLOBAL VITILIGO TREATMENT MARKET, FOR SEGMENTAL VITILIGO, BY REGION, 2019–2030 (USD BILLION) TABLE 4 GLOBAL VITILIGO TREATMENT MARKET, FOR NON-SEGMENTAL VITILIGO, BY REGION, 2019–2030 (USD BILLION) TABLE 5 GLOBAL VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2019–2030 (USD BILLION) TABLE 6 GLOBAL VITILIGO TREATMENT MARKET, FOR THERAPY, BY REGION, 2019–2030 (USD BILLION) TABLE 7 GLOBAL VITILIGO TREATMENT MARKET, FOR DEPIGMENTATION, BY REGION, 2019–2030 (USD BILLION) TABLE 8 GLOBAL VITILIGO TREATMENT MARKET, FOR LIGHT, BY REGION, 2019–2030 (USD BILLION) TABLE 9 GLOBAL VITILIGO TREATMENT MARKET, FOR SURGERY, BY REGION, 2019–2030 (USD BILLION) TABLE 10 GLOBAL VITILIGO TREATMENT MARKET, FOR SKIN GRAFTING, BY REGION, 2019–2030 (USD BILLION) TABLE 11 GLOBAL VITILIGO TREATMENT MARKET, FOR BLISTER GRAFTING, BY REGION, 2019–2030 (USD BILLION) TABLE 12 GLOBAL VITILIGO TREATMENT MARKET, FOR MICRO-PIGMENTATION, BY REGION, 2019–2030 (USD BILLION) TABLE 13 GLOBAL VITILIGO TREATMENT MARKET, FOR MEDICATION, BY REGION, 2019–2030 (USD BILLION) TABLE 14 GLOBAL VITILIGO TREATMENT MARKET, FOR TOPICAL CORTICOSTEROIDS, BY REGION, 2019–2030 (USD BILLION) TABLE 15 GLOBAL VITILIGO TREATMENT MARKET, FOR IMMUNOSUPPRESSIVE, BY REGION, 2019–2030 (USD BILLION) TABLE 16 GLOBAL VITILIGO TREATMENT MARKET, BY END USER, 2019–2030 (USD BILLION) TABLE 17 GLOBAL VITILIGO TREATMENT MARKET, FOR HOSPITALS, BY REGION, 2019–2030 (USD BILLION) TABLE 18 GLOBAL VITILIGO TREATMENT MARKET, FOR AMBULATORY CLINICS, BY REGION, 2019–2030 (USD BILLION) TABLE 19 GLOBAL VITILIGO TREATMENT MARKET, FOR OTHERS, BY REGION, 2019–2030 (USD BILLION) TABLE 20 GLOBAL: VITILIGO TREATMENT MARKET, BY REGION, 2019–2030 (USD BILLION) TABLE 21 NORTH AMERICA: VITILIGO TREATMENT MARKET, BY COUNTRY, 2019–2030 (USD BILLION) TABLE 22 NORTH AMERICA: VITILIGO TREATMENT MARKET, BY TYPE, 2019–2030 (USD BILLION) TABLE 23 NORTH AMERICA: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2019–2030 (USD BILLION) TABLE 24 NORTH AMERICA: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2019–2030 (USD BILLION) TABLE 25 NORTH AMERICA: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2019–2030 (USD BILLION) TABLE 26 NORTH AMERICA: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2030 (USD BILLION) TABLE 27 NORTH AMERICA: VITILIGO TREATMENT MARKET, BY END USER, 2019–2030 (USD BILLION) TABLE 28 US: VITILIGO TREATMENT MARKET, BY TYPE, 2019–2030 (USD BILLION) TABLE 29 US: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2019–2030 (USD BILLION) TABLE 30 US: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2019–2030 (USD BILLION) TABLE 31 US: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2019–2030 (USD BILLION) TABLE 32 US: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2030 (USD BILLION) TABLE 33 US: VITILIGO TREATMENT MARKET, BY END USER, 2019–2030 (USD BILLION) TABLE 34 CANADA: VITILIGO TREATMENT MARKET, BY TYPE, 2019–2030 (USD BILLION) TABLE 35 CANADA: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2019–2030 (USD BILLION) TABLE 36 CANADA: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2019–2030 (USD BILLION) TABLE 37 CANADA: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2019–2030 (USD BILLION) TABLE 38 CANADA: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2030 (USD BILLION) TABLE 39 CANADA: VITILIGO TREATMENT MARKET, BY END USER, 2019–2030 (USD BILLION) TABLE 40 EUROPE: VITILIGO TREATMENT MARKET, BY COUNTRY, 2019–2030 (USD BILLION) TABLE 41 EUROPE: VITILIGO TREATMENT MARKET, BY TYPE, 2019–2030 (USD BILLION) TABLE 42 EUROPE: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2019–2030 (USD BILLION) TABLE 43 EUROPE: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2019–2030 (USD BILLION) TABLE 44 EUROPE: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2019–2030 (USD BILLION) TABLE 45 EUROPE: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2030 (USD BILLION) TABLE 46 EUROPE: VITILIGO TREATMENT MARKET, BY END USER, 2019–2030 (USD BILLION) TABLE 47 GERMANY: VITILIGO TREATMENT MARKET, BY TYPE, 2019–2030 (USD BILLION) TABLE 48 GERMANY: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2019–2030 (USD BILLION) TABLE 49 GERMANY: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2019–2030 (USD BILLION) TABLE 50 GERMANY: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2019–2030 (USD BILLION) TABLE 51 GERMANY: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2030 (USD BILLION) TABLE 52 GERMANY: VITILIGO TREATMENT MARKET, BY END USER, 2019–2030 (USD BILLION) TABLE 53 FRANCE: VITILIGO TREATMENT MARKET, BY TYPE, 2019–2030 (USD BILLION) TABLE 54 FRANCE: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2019–2030 (USD BILLION) TABLE 55 FRANCE: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2019–2030 (USD BILLION) TABLE 56 FRANCE: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2019–2030 (USD BILLION) TABLE 57 FRANCE: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2030 (USD BILLION) TABLE 58 FRANCE: VITILIGO TREATMENT MARKET, BY END USER, 2019–2030 (USD BILLION) TABLE 59 UK: VITILIGO TREATMENT MARKET, BY TYPE, 2019–2030 (USD BILLION) TABLE 60 UK: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2019–2030 (USD BILLION) TABLE 61 UK: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2019–2030 (USD BILLION) TABLE 62 UK: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2019–2030 (USD BILLION) TABLE 63 UK: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2030 (USD BILLION) TABLE 64 UK: VITILIGO TREATMENT MARKET, BY END USER, 2019–2030 (USD BILLION) TABLE 65 ITALY: VITILIGO TREATMENT MARKET, BY TYPE, 2019–2030 (USD BILLION) TABLE 66 ITALY: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2019–2030 (USD BILLION) TABLE 67 ITALY: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2019–2030 (USD BILLION) TABLE 68 ITALY: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2019–2030 (USD BILLION) TABLE 69 ITALY: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2030 (USD BILLION) TABLE 70 ITALY: VITILIGO TREATMENT MARKET, BY END USER, 2019–2030 (USD BILLION) TABLE 71 SPAIN: VITILIGO TREATMENT MARKET, BY TYPE, 2019–2030 (USD BILLION) TABLE 72 SPAIN: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2019–2030 (USD BILLION) TABLE 73 SPAIN: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2019–2030 (USD BILLION) TABLE 74 SPAIN: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2019–2030 (USD BILLION) TABLE 75 SPAIN: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2030 (USD BILLION) TABLE 76 SPAIN: VITILIGO TREATMENT MARKET, BY END USER, 2019–2030 (USD BILLION) TABLE 77 REST OF EUROPE: VITILIGO TREATMENT MARKET, BY TYPE, 2019–2030 (USD BILLION) TABLE 78 REST OF EUROPE: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2019–2030 (USD BILLION) TABLE 79 REST OF EUROPE: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2019–2030 (USD BILLION) TABLE 80 REST OF EUROPE: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2019–2030 (USD BILLION) TABLE 81 REST OF EUROPE: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2030 (USD BILLION) TABLE 82 REST OF EUROPE: VITILIGO TREATMENT MARKET, BY END USER, 2019–2030 (USD BILLION) TABLE 83 ASIA-PACIFIC: VITILIGO TREATMENT MARKET, BY COUNTRY, 2019-2030 (USD BILLION) TABLE 84 ASIA-PACIFIC: VITILIGO TREATMENT MARKET, BY TYPE, 2019-2030 (USD BILLION) TABLE 85 ASIA-PACIFIC: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2019-2030 (USD BILLION) TABLE 86 ASIA-PACIFIC: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2019-2030 (USD BILLION) TABLE 87 ASIA-PACIFIC: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2019-2030 (USD BILLION) TABLE 88 ASIA-PACIFIC: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD BILLION) TABLE 89 ASIA-PACIFIC: VITILIGO TREATMENT MARKET, BY END USER, 2019-2030 (USD BILLION) TABLE 90 CHINA: VITILIGO TREATMENT MARKET, BY TYPE, 2019-2030 (USD BILLION) TABLE 91 CHINA: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2019-2030 (USD BILLION) TABLE 92 CHINA: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2019-2030 (USD BILLION) TABLE 93 CHINA: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2019-2030 (USD BILLION) TABLE 94 CHINA: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD BILLION) TABLE 95 CHINA: VITILIGO TREATMENT MARKET, BY END USER, 2019-2030 (USD BILLION) TABLE 96 JAPAN: VITILIGO TREATMENT MARKET, BY TYPE, 2019-2030 (USD BILLION) TABLE 97 JAPAN: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2019-2030 (USD BILLION) TABLE 98 JAPAN: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2019-2030 (USD BILLION) TABLE 99 JAPAN: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2019-2030 (USD BILLION) TABLE 100 JAPAN: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD BILLION) TABLE 101 JAPAN: VITILIGO TREATMENT MARKET, BY END USER, 2019-2030 (USD BILLION) TABLE 102 INDIA: VITILIGO TREATMENT MARKET, BY TYPE, 2019-2030 (USD BILLION) TABLE 103 INDIA: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2019-2030 (USD BILLION) TABLE 104 INDIA: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2019-2030 (USD BILLION) TABLE 105 INDIA: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2019-2030 (USD BILLION) TABLE 106 INDIA: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD BILLION) TABLE 107 INDIA: VITILIGO TREATMENT MARKET, BY END USER, 2019-2030 (USD BILLION) TABLE 108 SOUTH KOREA: VITILIGO TREATMENT MARKET, BY TYPE, 2019-2030 (USD BILLION) TABLE 109 SOUTH KOREA: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2019-2030 (USD BILLION) TABLE 110 SOUTH KOREA: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2019-2030 (USD BILLION) TABLE 111 SOUTH KOREA: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2019-2030 (USD BILLION) TABLE 112 SOUTH KOREA: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD BILLION) TABLE 113 SOUTH KOREA: VITILIGO TREATMENT MARKET, BY END USER, 2019-2030 (USD BILLION) TABLE 114 AUSTRALIA: VITILIGO TREATMENT MARKET, BY TYPE, 2019-2030 (USD BILLION) TABLE 115 AUSTRALIA: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2019-2030 (USD BILLION) TABLE 116 AUSTRALIA: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2019-2030 (USD BILLION) TABLE 117 AUSTRALIA: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2019-2030 (USD BILLION) TABLE 118 AUSTRALIA: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD BILLION) TABLE 119 AUSTRALIA: VITILIGO TREATMENT MARKET, BY END USER, 2019-2030 (USD BILLION) TABLE 120 REST OF ASIA-PACIFIC: VITILIGO TREATMENT MARKET, BY TYPE, 2019-2030 (USD BILLION) TABLE 121 REST OF ASIA-PACIFIC: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2019-2030 (USD BILLION) TABLE 122 REST OF ASIA-PACIFIC: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2019-2030 (USD BILLION) TABLE 123 REST OF ASIA-PACIFIC: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2019-2030 (USD BILLION) TABLE 124 REST OF ASIA-PACIFIC: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD BILLION) TABLE 125 REST OF ASIA-PACIFIC: VITILIGO TREATMENT MARKET, BY END USER, 2019-2030 (USD BILLION) TABLE 126 REST OF THE WORLD: VITILIGO TREATMENT MARKET, BY COUNTRY, 2019-2030 (USD BILLION) TABLE 127 REST OF THE WORLD: VITILIGO TREATMENT MARKET, BY TYPE, 2019-2030 (USD BILLION) TABLE 128 REST OF THE WORLD: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2019-2030 (USD BILLION) TABLE 129 REST OF THE WORLD: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2019-2030 (USD BILLION) TABLE 130 REST OF THE WORLD: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2019-2030 (USD BILLION) TABLE 131 REST OF THE WORLD: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD BILLION) TABLE 132 REST OF THE WORLD: VITILIGO TREATMENT MARKET, BY END USER, 2019-2030 (USD BILLION) TABLE 133 MIDDLE EAST: VITILIGO TREATMENT MARKET, BY TYPE, 2019-2030 (USD BILLION) TABLE 134 MIDDLE EAST: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2019-2030 (USD BILLION) TABLE 135 MIDDLE EAST: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2019-2030 (USD BILLION) TABLE 136 MIDDLE EAST: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2019-2030 (USD BILLION) TABLE 137 MIDDLE EAST: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD BILLION) TABLE 138 MIDDLE EAST: VITILIGO TREATMENT MARKET, BY END USER, 2019-2030 (USD BILLION) TABLE 139 AFRICA: VITILIGO TREATMENT MARKET, BY TYPE, 2019-2030 (USD BILLION) TABLE 140 AFRICA: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2019-2030 (USD BILLION) TABLE 141 AFRICA: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2019-2030 (USD BILLION) TABLE 142 AFRICA: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2019-2030 (USD BILLION) TABLE 143 AFRICA: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD BILLION) TABLE 144 AFRICA: VITILIGO TREATMENT MARKET, BY END USER, 2019-2030 (USD BILLION) TABLE 145 LATIN AMERICA: VITILIGO TREATMENT MARKET, BY TYPE, 2019-2030 (USD BILLION) TABLE 146 LATIN AMERICA: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2019-2030 (USD BILLION) TABLE 147 LATIN AMERICA: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2019-2030 (USD BILLION) TABLE 148 LATIN AMERICA: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2019-2030 (USD BILLION) TABLE 149 LATIN AMERICA: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD BILLION) TABLE 150 LATIN AMERICA: VITILIGO TREATMENT MARKET, BY END USER, 2019-2030 (USD BILLION) TABLE 151 MAJOR MANUFACTURERS IN VITILIGO TREATMENT MARKET TABLE 152 MOST ACTIVE PLAYER IN VITILIGO TREATMENT MARKET TABLE 153 PRODUCT APPROVALS/PRODUCT LAUNCHES/DRUG PIPELINE TABLE 154 MERGERS & ACQUISITIONS TABLE 155 INCYTE: PRODUCTS OFFERED TABLE 156 INCYTE: KEY DEVELOPMENTS TABLE 157 BAUSCH HEALTH COMPANIES INC.: PRODUCTS OFFERED TABLE 158 KONINKLIJKE PHILIPS N.V.: PRODUCTS OFFERED TABLE 159 DR. REDDY'S LABORATORIES LTD.: PRODUCTS OFFERED TABLE 160 STRATA SKIN SCIENCES: PRODUCTS OFFERED TABLE 161 STRATA SKIN SCIENCES: KEY DEVELOPMENTS TABLE 162 CLINUVEL PHARMACEUTICALS LTD: PRODUCTS OFFERED TABLE 163 ISSAR PHARMACEUTICALS PVT. LTD.: PRODUCTS OFFERED TABLE 164 KERNEL MEDICAL EQUIPMENT CO., LTD.: PRODUCTS OFFERED TABLE 165 LIGHTSOURCES: PRODUCTS OFFERED TABLE 166 ROIVANT SCIENCES LTD.: PRODUCTS OFFERED LIST OF FIGURES FIGURE 1 GLOBAL VITILIGO TREATMENT MARKET STRUCTURE FIGURE 2 BOTTOM-UP AND TOP-DOWN APPROACHES FIGURE 3 MARKET DYNAMICS: GLOBAL VITILIGO TREATMENT MARKET FIGURE 4 DRIVERS: IMPACT ANALYSIS FIGURE 5 RESTRAINT: IMPACT ANALYSIS FIGURE 6 VALUE CHAIN ANALYSIS: GLOBAL VITILIGO TREATMENT MARKET FIGURE 7 PORTER'S FIVE FORCES ANALYSIS: GLOBAL VITILIGO TREATMENT MARKET FIGURE 8 GLOBAL VITILIGO TREATMENT MARKET, BY TYPE, 2022 AND 2030 (USD BILLION) FIGURE 9 GLOBAL VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2022 AND 2030 (USD BILLION) FIGURE 10 GLOBAL VITILIGO TREATMENT MARKET, BY END USER, 2022 AND 2030 (USD BILLION) FIGURE 11 GLOBAL: VITILIGO TREATMENT MARKET, BY REGION 2022 AND 2030 (USD BILLION) FIGURE 12 GLOBAL: VITILIGO TREATMENT MARKET SHARE (%), BY REGION, 2022 FIGURE 13 NORTH AMERICA: VITILIGO TREATMENT MARKET SHARE (%), BY COUNTRY 2022 FIGURE 14 EUROPE: VITILIGO TREATMENT MARKET SHARE (%), BY COUNTRY 2022 FIGURE 15 ASIA-PACIFIC: VITILIGO TREATMENT MARKET SHARE (%), BY COUNTRY, 2022 FIGURE 16 REST OF THE WORLD: VITILIGO TREATMENT MARKET SHARE (%), BY COUNTRY, 2022 FIGURE 17 BENCHMARKING OF MAJOR COMPETITORS FIGURE 18 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN VITILIGO TREATMENT MARKET FIGURE 19 GLOBAL VITILIGO TREATMENT MARKET: COMPETITIVE LANDSCAPE FIGURE 20 MAJOR PLAYERS SALES & OPERATING INCOME, 2022 FIGURE 21 MAJOR PLAYERS R&D EXPENDITURE, 2022 FIGURE 22 INCYTE: FINANCIAL OVERVIEW SNAPSHOT FIGURE 23 INCYTE: SWOT ANALYSIS FIGURE 24 BAUSCH HEALTH COMPANIES INC.: FINANCIAL OVERVIEW SNAPSHOT FIGURE 25 BAUSCH HEALTH COMPANIES INC.: SWOT ANALYSIS FIGURE 26 KONINKLIJKE PHILIPS N.V.: FINANCIAL OVERVIEW SNAPSHOT FIGURE 27 KONINKLIJKE PHILIPS N.V.: SWOT ANALYSIS FIGURE 28 DR. REDDY'S LABORATORIES LTD.: FINANCIAL OVERVIEW SNAPSHOT FIGURE 29 DR. REDDY'S LABORATORIES LTD.: SWOT ANALYSIS FIGURE 30 STRATA SKIN SCIENCES: FINANCIAL OVERVIEW SNAPSHOT FIGURE 31 CLINUVEL PHARMACEUTICALS LTD: FINANCIAL OVERVIEW SNAPSHOT FIGURE 32 CLINUVEL PHARMACEUTICALS LTD: SWOT ANALYSIS FIGURE 33 ROIVANT SCIENCES LTD.: FINANCIAL OVERVIEW SNAPSHOT FIGURE 34 ROIVANT SCIENCES LTD.: PRODUCTS OFFERED

提及公司

Incyte (US)Bausch Health Companies Inc (Canada)Koninklijke Philips N.V. (Netherlands)Reddy's Laboratories Ltd (India)Strata Skin Sciences (US)Clinuvel Pharmaceuticals Ltd (Australia)ISSAR pharmaceuticals Pvt. Ltd (India)Kernel Medical Equipment CO.LTD (China)LightSources (US)and Roivant Sciences Ltd. (Switzerland).

同分類最新報告(醫療與生命科學)

量子訊息有限公司為 Market Research Future 在台灣的授權代理,提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們